PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Recruiting now · Phase 2
Conditions studied: CRC (Colorectal Cancer)
In brief
PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.
Key facts
- Study ID
- NCT07133750
- Run by
- Biotheus Inc.
- People needed
- 100
- Starts
- 2025-08-19
- Expected to finish
- 2030-05-01
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Peking University First Hospital — Beijing, Beijing Municipality, China (enrolling)
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (enrolling)
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China (enrolling)
- Hubei Cancer Hospital — Wuhan, Hubei, China (enrolling)
- Jilin Cancer Hospital — Changchun, Jilin, China (enrolling)
- Cancer Hospital of Shandong First Medical University — Jinan, Shandong, China (enrolling)
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China (enrolling)
- Sichuan Cancer Hospital — Chengdu, Sichuan, China (enrolling)
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.